ASH News Daily - Sunday, December 11, 2011 - (Page C-9)

Complete Hematologic Response Complete Cytogenetic Response Major Molecular Response Undetectable BCR-ABL Transcripts The Path in CML, sponsored by Novartis Oncology, is an unprecedented collaborative research initiative focused on keeping Ph+ CML undetectable in the maximum number of patients with the hope of one day achieving treatment-free survival: the ability to stop therapy without fear of disease recurrence. We have been committed to CML research for the past 10 years, and will continue to work toward advancing the science. Through our collaborative partnerships with equally dedicated medical experts, basic researchers, patients, and advocacy groups, we aspire to discover new biomarkers, optimize molecular monitoring methods, develop new and different treatment strategies, and investigate different approaches to the overall management of Ph+ CML. We’re on a mission to change the path in Ph+ CML… and we’ll stop at nothing. 10/21/11 11:27 AM

Table of Contents for the Digital Edition of ASH News Daily - Sunday, December 11, 2011

ASH News Daily - Sunday, December 11, 2011

https://www.nxtbookmedia.com